Fresenius SE KGaA (XTER:FRE) Change In Receivables: €-285 Mil (TTM As of Mar. 2026)


XTER:FRE Fresenius SE & Co KGaA XTER:FRE
72 GF Score
Price €42.57
GF Value €36.60
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Fresenius SE KGaA Change In Receivables?

Fresenius SE KGaA XTER:FRE +0.83% 72 Change In Receivables is €-285 Mil as of Mar. 2026. GuruFocus rates XTER:FRE with a GF Score™ of 72/100 and a GF Value™ of €36.60 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Fresenius SE KGaA's change in receivables for the quarter that ended in Mar. 2026 was €-383 Mil. It means Fresenius SE KGaA's Accounts Receivable increased by €383 Mil from Dec. 2025 to Mar. 2026 .

Fresenius SE KGaA's change in receivables for the fiscal year that ended in Dec. 2025 was €-220 Mil. It means Fresenius SE KGaA's Accounts Receivable increased by €220 Mil from Dec. 2024 to Dec. 2025 .

Fresenius SE KGaA's Accounts Receivable for the quarter that ended in Mar. 2026 was €3,962 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Fresenius SE KGaA's Days Sales Outstanding for the three months ended in Mar. 2026 was 62.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Fresenius SE KGaA's liquidation value for the three months ended in Mar. 2026 was €-13,620 Mil.

Fresenius SE KGaA  (XTER:FRE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Fresenius SE KGaA's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3962/5818*91
=62.14

2. In Ben Graham's calculation of liquidation value, Fresenius SE KGaA's accounts receivable are only considered to be worth 75% of book value:

Fresenius SE KGaA's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3949-21905+0.75 * 3962+0.5 * 2730
=-13,620

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius SE KGaA Change In Receivables Related Terms

Fresenius SE KGaA Change In Receivables Historical Data

* Premium members only.

The historical data trend for Fresenius SE KGaA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fresenius SE KGaA Change In Receivables Chart

Fresenius SE KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.00 162.00 -387.00 43.00 -220.00

Fresenius SE KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -318.00 -141.00 -74.00 313.00 -383.00
XTER:FRE
72GF Score
Fresenius SE & Co KGaA XTER:FRE
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fresenius SE KGaA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-285 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €-285 Mil mean?
Fresenius SE KGaA (XTER:FRE) has a Change In Receivables of €-285 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Fresenius SE KGaA and its competitors.
Is Fresenius SE KGaA's Change In Receivables too high?
Fresenius SE KGaA's current Change In Receivables is €-285 Mil. Overall, Fresenius SE KGaA has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Change In Receivables compare to HCA and THC?
Fresenius SE KGaA's Change In Receivables of €-285 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Healthcare Providers & Services company?
A good Change In Receivables depends on the Healthcare Providers & Services industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Fresenius SE KGaA and its competitors. Fresenius SE KGaA's current Change In Receivables is €-285 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XTER:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is €36.60, compared to a current price of €42.57 — trading 16.3% above its estimated fair value. The current Change In Receivables is €-285 Mil. Fresenius SE KGaA's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Fresenius SE KGaA (XTER:FRE), the current Change In Receivables is €-285 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fresenius SE KGaA (XTER:FRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued. The current stock price of €42.57 is trading 16.3% above its estimated GF Value™ of €36.60. GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.

Key valuation signals for XTER:FRE:

  • Change In Receivables: €-285 Mil
  • GF Value™: €36.60 vs. price of €42.57 (16.3% above fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the XTER:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fresenius SE KGaA Business Description

Address Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
72GF Score

Get the complete analysis for XTER:FRE

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.57
Price
€36.60
GF Value